The EV Truck War Is Officially On
Motley Fool Money
00:00
Eli Lilly's Strategic Obesity Drug Acquisition
This chapter explores Eli Lilly's acquisition of an obesity drug maker as part of a $1.93 billion deal, emphasizing the rising market for obesity treatments in light of American obesity rates. It highlights the contrasts in societal views on drug pricing for obesity versus other diseases like Alzheimer's, along with investment strategies in a competitive pharmaceutical landscape.
Play episode from 09:53
Transcript
